Orchid Pharma Limited has informed the Exchange about Investor Presentation

Orchid Pharma released its Q4 and FY26 investor presentation. The company reported FY26 standalone revenue of Rs 811 Cr, down 12% YoY from Rs 922 Cr. EBITDA declined 36% to Rs 101 Cr with margins contracting from 17% to 12%. PAT fell 58% to Rs 45 Cr from Rs 106 Cr. However, Q4 showed sequential improvement with EBITDA at Rs 42 Cr (+5% QoQ) and PAT at Rs 30 Cr. The company is undergoing a merger with Dhanuka to create an integrated anti-infectives platform. Key strategic initiatives include backward integration into 7ACA (1,000 MT capacity, commissioning FY27), launching 5-6 sterile products in the US by 2030, and the Cefiderocol access project ($20-25 Mn investment). Capital allocation is 73% toward 7ACA integration, 20% toward FDF capability, and 5% toward R&D. Orchid positions itself as India's only USFDA-approved sterile cephalosporin manufacturer with EXBLIFEP as India's only novel antibiotic.